Zentiva board rejects PPF bid; Judge upholds AZ fraud verdict

> Zentiva recommended its shareholders reject PPF's buyout bid of 950 Czech crowns per share as it fails to reflect Zentiva's underlying value and future prospects; while noting Sanofi-Aventis' counteroffer of 1,050 crowns, the company didn't comment on further. Report

> A state judge upheld the fraud verdict that Alabama won against AstraZeneca in a Medicaid drug pricing suit, but ruled today the punitive damages were too high, trimming the total judgment to $160 million. Report

> India's patent office rejected German pharma major Boehringer Ingelheim’s product patent application for its pediatric form of the anti-AIDS drug Nevirapine. Report

> Boston Scientific has agreed to sell pieces of its investment portfolio to raise a total of $140 million before taxes and help pay off debt, but also force the medical device maker to record losses against second-quarter earnings. Report

> Moody's Investors Service assigned an 'Aaa' rating to Johnson & Johnson's new senior unsecured note offering. Report

> Perrigo got final Food and Drug Administration approval for a generic version of Johnson & Johnson's allergic rhinitis treatment, Zyrtec Syrup. Report

> Cambridge, MA-based Alnylam Pharmaceuticals has signed on to a $93 million pact with Japan's Kyowa Hakko Kogyo to develop an Respiratory Syncytial Virus therapy for Asian markets. Report

> Canada is giving about $98 million to the Canadian Cancer Stem Cell Consortium so that the country's stem cell scientists can work in tandem with the California Institute for Regenerative Medicine. Report

> The Governator turned up at BIO on Tuesday, winning over a full house of star-struck biotech executives with a few bad jokes and a big huzzah for the state's $3 billion stem cell initiative. Report

> Investors took a big bite out of Discovery Laboratories' stock value after the developer announced that it would delay a response to the FDA on its experimental lung drug for infants by two months. Report

> Carl Icahn's high noon showdown with the executive team at Biogen Idec ended in a rare defeat for the Wall Street spoiler. Report

And Finally ... Didn't make it to San Diego for BIO this year? Then take a look at these show floor photos to see what you missed. Photo slideshow

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.